Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer

Authors: Junji Tsurutani, Fumikata Hara, Masahiro Kitada, Masato Takahashi, Yuichiro Kikawa, Hiroaki Kato, Eiko Sakata, Yoichi Naito, Yoshie Hasegawa, Tsuyoshi Saito, Tsutomu Iwasa, Naruto Taira, Tsutomu Takashima, Kosuke Kashiwabara, Tomohiko Aihara, Hirofumi Mukai

Source: Breast, Vol 55, Iss , Pp 63-68 (2021)

Subject Terms: Nab-paclitaxel, Nanoparticle albumin–bound paclitaxel, Metastatic breast cancer, Solvent-base paclitaxel, Chemotherapy-induced peripheral neuropathy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S0960977620302319; https://doaj.org/toc/1532-3080

Access URL: https://doaj.org/article/47ae3af95d7143318f7fa81b47457151